NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Drug-drug Interaction Study of Midazolam and AT-527 (R07496998)

NCT04865445

CompletedPhase 1

Sponsor: Atea Pharmaceuticals, Inc.

Conditions: Healthy Volunteer Study

Interventions: AT-527 550 mg + midazolam, AT-527 550 mg + midazolam

Countries: Canada

Drug-drug interaction study of midazolam and AT-527 (R07496998)

Eligibility overview

Sex: ALL

Age: 18 Years to 65 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug
* Females must have a negative pregnancy test at Screening and prior to dosing
* Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2
* Willing to comply with the study requirements and to provide written informed consent

Exclusion Criteria:

* Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2
* Abuse of alcohol or drugs
* Use of other investigational drugs within 28 days of dosing
* Concomitant use of prescription medications, or systemic over-the-counter medications
* Other clinically significant medical conditions or laboratory abnormalities

Locations (1)

Montreal, Montreal, Quebec, Canada